Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.Imaging confirms the ...

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment ...

A 4-time WWE Champion has talked about his health issues and revealed that he has atrophy in both arms and is in constant pain. The star made the revelation in a recent interview. Kurt Angle was ...

Tumstatin serves as an anti-inflammatory and anti-vascular endothelial growth factor (VEGF) agent by targeting integrin receptors while transferrin aims the drug towards the choroid and retina ... for ...

Transferrin, the second of the two parts, targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. Shankar Musunuri, PhD, MBA, chairman, CEO, and co-founder of ...